| Literature DB >> 29360429 |
Mitsuru Yanai1, Maiko Ogasawasa2, Yuta Hayashi2, Kiyozumi Suzuki2, Hiromichi Takahashi3, Atsushi Satomura3.
Abstract
OBJECTIVES: Corynebacterium spp. are becoming recognized as pathogens that potentially cause various infections. We aimed to evaluate the clinical characteristics associated with Corynebacterium spp. bacteremia. PATIENTS AND METHODS: We retrospectively reviewed the medical records of all adult patients who had positive blood cultures for Corynebacterium spp. in a single university hospital between January 2014 and December 2016. Patients were divided into a bacteremia group and a contamination group based on microbiological test results and clinical characteristics. Patients' characteristics, antimicrobial susceptibility of isolated species, antimicrobials administered, and patient outcomes were evaluated.Entities:
Keywords: Blood culture; Bloodstream infection; Contamination; Corynebacterium species
Mesh:
Substances:
Year: 2018 PMID: 29360429 PMCID: PMC9425686 DOI: 10.1016/j.bjid.2017.12.002
Source DB: PubMed Journal: Braz J Infect Dis ISSN: 1413-8670 Impact factor: 3.257
Characteristics of patients with bacteremia or blood culture contamination with Corynebacterium spp.
| Total | Bacteremia | Contamination | ||
|---|---|---|---|---|
| Number of cases, | 63 | 28 | 35 | |
| Age (years), median (IQR) | 73 (62.0–81.5) | 65.5 (57.3–77.0) | 75 (70.0–83.0) | 0.023 |
| Male:female ratio | 47:16 | 22:6 | 25:10 | 0.517 |
| Department, | ||||
| Emergency and critical care medicine | 14 (22) | 3 (11) | 11 (31) | 0.049 |
| Gastrointestinal medicine | 8 (13) | 4 (14) | 4 (11) | |
| Hematology and rheumatology | 8(13) | 6 (21) | 2 (6) | |
| Cardiovascular surgery | 7 (11) | 5 (18) | 2 (6) | |
| Nephrology | 5 (8) | 4 (14) | 1 (3) | |
| Cardiovascular medicine | 5 (8) | 2 (7) | 3 (9) | |
| Digestive surgery | 4 (6) | 2 (7) | 2 (6) | |
| General medicine | 3 (5) | 0 (07) | 3 (9) | |
| Other | 9 (14) | 2 (7) | 7 (20) | |
| Underlying diseases, | ||||
| Malignancy | 22 | 13 | 9 | 0.086 |
| DM | 6 | 4 | 2 | 0.249 |
| ESRD on dialysis therapy | 12 | 8 | 4 | 0.085 |
| LC | 3 | 2 | 1 | 0.427 |
| Vascular catheter placement, | ||||
| CV catheter | 39 (62) | 21 (75) | 18 (51) | |
| Peripheral catheter | 5 (8) | 4 (14) | 1 (3) | |
| No catheter | 19 (30) | 3 (11) | 16 (46) | 0.002 |
| Time from admission to sampling (days), median (IQR) | 25 (6–49) | 36 (15–61) | 13 (0–31) | 0.006 |
| Time to positive culture detection | 1 (1–2) | 1 (1–1) | 2 (1– 2) | 0.009 |
| Temperature >38 °C, | 51 (81) | 25 (89) | 26 (74) | 0.132 |
| WBC count (×109/L) | 9.2 (5.0–13.2) | 8.9 (3.1–12.5) | 9.2 (7.3–13.8) | 0.290 |
| CRP (mg/dL), median (IQR) | 6.6 (3.3–15.9) | 6.1 (3.2–13.5) | 7.1 (4.4–16.4) | 0.481 |
| Hospital stay (days), median (IQR) | 57 (27–97) | 81 (38–135) | 36 (17–63) | 0.002 |
Abbreviations: IQR, interquartile range; DM, diabetes mellitus; ESRD, end-stage renal disease; LC, liver cirrhosis; CV, central venous; WBC, white blood cell; CRP, C-reactive protein.
Other: urology (n = 2), respiratory medicine (n = 2), dermatology (n = 2), orthopedics (n = 1), respiratory surgery (n = 1), and neurosurgery (n = 1) departments.
Final identification of Corynebacterium spp., blood culture positivity pattern, and sites from which specimens, taken simultaneously with blood specimens, cultured positive for Corynebacterium spp.
| Total ( | Bacteremia ( | Contamination ( | |
|---|---|---|---|
| | 38 | 22 | 16 |
| | 6 | 4 | 2 |
| | 2 | 1 | 1 |
| | 19 | 1 | 18 |
| 2/2 | 23 | 23 | 0 |
| 1/2 | 39 | 5 | 34 |
| 1/1 | 3 | 0 | 3 |
| Catheter tip | 11 | 9 | 2 |
| Sputum | 5 | 2 | 3 |
| Wound (pus) | 3 | 2 | 1 |
| Urine | 2 | 2 | 0 |
| Drain | 1 | 1 | 0 |
| None | 45 | 15 | 30 |
In two patients, two species (C. striatum and Corynebacterium sp.) were identified in the same blood culture sampling.
In four cases, the same species were isolated from multiple sites (three cases in the bacteremia group and one case in the contamination group).
Antibiotic susceptibility of Corynebacterium spp. isolated from blood culture specimens (susceptible/tested (%)).
| ABPC | ABPC/SBT | IPM/CS | GM | EM | CLDM | MINO | VCM | TEIC | ST | LVFX | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2/31 (7) | 5/31 (16) | 5/31 (16) | 22/22 (100) | 3/22 (14) | 3/31 (10) | 31/31 (100) | 31/31 (100) | 31/31 (100) | 27/31 (87) | 1/31 (3) | |
| 0/6 (0) | 0/6 (0) | 1/6 (17) | 1/6 (17) | 0/6 (0) | 0/6 (0) | 4/6 (67) | 6/6 (100) | 6/6 (100) | 4/6 (67) | 0/6 (0) | |
| 0/2 (0) | 0/2 (0) | 0/2 (0) | 2/2 (100) | 2/2 (100) | 2/2 (100) | 2/2 (100) | 2/2 (100) | 2/2 (100) | 2/2 (100) | 0/2 (0) | |
| 0/1 (0) | 0/1 (0) | 1/1 (100) | 1/1 (100) | 0/1 (0) | 0/1 (0) | 1/1 (100) | 1/1 (100) | 1/1 (100) | 0/1 (0) | 0/1 (0) |
Abbreviations: ABPC, ampicillin; ABPC/SBT, ampicillin–sulbactam; IPM/CS, imipenem/cilastatin; GM, gentamicin; EM, erythromycin; CLDM, clindamycin; MINO, minocycline; VCM, vancomycin; TEIC, teicoplanin; ST, sulfamethoxazole–trimethoprim; LVFX, levofloxacin.
Antimicrobial treatment and outcome of patients with bacteremia caused by Corynebacterium spp.
| Antimicrobial drug | Outcome | ||
|---|---|---|---|
| Cured | Died | ||
| Vancomycin | 19 (68%) | 17 | 2 |
| Teicoplanin | 4 (14%) | 3 | 1 |
| Daptomycin | 2 (7%) | 2 | 0 |
| Linezolid | 1 (4%) | 1 | 0 |
| Minocycline | 1 (4%) | 1 | 0 |
| None | 1 (4%) | 0 | 1 |